Polatuzumab Clinical Trials
4 recruitingDrug
Phase 23Phase 11
Showing 1–4 of 4 trials
Recruiting
Phase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center42 enrolled7 locationsNCT06765317
Recruiting
Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Non-Hodgkin LymphomaLymphoma
National Cancer Institute (NCI)55 enrolled1 locationNCT04739813
Recruiting
Phase 2
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
LymphomaLymphoma, Large B-Cell, Diffuse
Jennifer Crombie, MD41 enrolled3 locationsNCT05800366
Recruiting
Phase 2
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Refractory Non-Hodgkin LymphomaRelapsed Non Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
Lazaros Lekakis22 enrolled1 locationNCT05260957